Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics has issued its 2026 proxy for the Annual Meeting to be held on May 27, 2026 at 9:00 a.m. Central Time in Chicago. Stockholders of record as of April 2, 2026, when 114,017,755 common shares were outstanding, may vote.
Investors are asked to elect six directors for one-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, and choose how often to hold advisory votes on executive pay. The Board recommends voting “FOR ALL” director nominees, “FOR” auditor ratification, and “1 YEAR” for the say‑on‑frequency proposal.
Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.
The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.
Perspective Therapeutics, Inc. describes its business as a clinical-stage radiopharmaceutical company developing precision targeted alpha therapies for cancer. Its platform centers on Lead‑212 (212Pb) therapeutics paired with Lead‑203 (203Pb) imaging to personalize treatment and limit damage to healthy tissue.
The company’s lead programs target neuroendocrine tumors (VMT‑α‑NET), metastatic melanoma (VMT01) and FAP‑α–expressing solid tumors (PSV359), all in Phase 1/2a trials. It highlights Fast Track designations, early clinical signals, and a 2024 option and funding agreement with an affiliate of Lantheus for VMT‑α‑NET and earlier PSMA/GRPR assets.
Perspective is building a distributed manufacturing network using proprietary 212Pb generators, facilities in Iowa and New Jersey, and new sites in Houston, Chicago and Los Angeles. The filing emphasizes substantial ongoing losses, the need for significant additional capital, clinical, regulatory and manufacturing risks, and stock price volatility. As of March 12, 2026, common shares outstanding were 113,933,436.
Perspective Therapeutics reported a larger net loss for 2025 while advancing its radiopharmaceutical pipeline and strengthening its balance sheet. Net loss was $103.1 million, or $1.40 per share, compared with $79.3 million, or $1.23 per share in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $84.2 million, up about 102%, as the company expanded clinical activities for its VMT-α-NET, VMT01 and PSV359 programs and recorded a $10.0 million non-cash impairment on a deprioritized preclinical asset. General and administrative expenses increased to $30.2 million from $26.6 million.
Cash, cash equivalents and short-term investments were about $145 million as of December 31, 2025, down from $227 million a year earlier. In February 2026, the company closed an underwritten equity offering with net proceeds of approximately $164 million, and now expects its cash resources to fund planned clinical milestones and operations into late 2027.
Perspective Therapeutics, Inc. ownership disclosure: Avidity reporting group states shared beneficial ownership of 6,049,999 shares of Common Stock, representing 5.3%.
The filing also shows Avidity Private Master Fund I LP holds 5,849,999 shares ( 5.1%). The report is signed by Michael Gregory on 03/10/2026.
Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.
Morich Frank reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.
The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.
Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Robert F. Williamson III reported receiving a grant of stock options representing 50,000 shares on March 2, 2026. The award was approved by the board on January 26, 2026 as his annual equity grant for 2026 and will vest in full on March 2, 2027, provided he continues serving through that date.
HENSON HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics director Heidi Henson was granted a stock option covering 50,000 shares on March 2, 2026. The grant was approved by the board as her annual 2026 equity award. The option vests in full on March 2, 2027, if she continues serving through that date.
Perspective Therapeutics director receives 2026 stock option grant. Director Lori A. Woods was granted a stock option to buy 50,000 shares at an exercise price of $0.0000 per share as her annual equity award for 2026. The option vests in full on March 2, 2027, assuming she continues to serve through the vesting date.